You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
A股異動丨腦機接口概念股走強,賽諾醫療漲超5%,中國植入式腦機接口啓動臨牀入組
A股市場腦機接口概念股集體走強,其中,冠昊生物漲超17%,海南海藥10CM漲停,北陸藥業漲超8%,翔宇醫療漲超7%,賽諾醫療、創新醫療漲超5%。消息面上,近日,在上海召開的第20屆亞洲神經腫瘤年會上,復旦大學附屬華山醫院院長毛穎教授透露,由上海華山醫院和北京宣武醫院牽頭的腦機接口臨牀隊列研究已啓動患者入組工作,旨在進一步驗證植入式腦機接口治療方案的有效性、安全性等關鍵問題。此外,上述會議傳出消息,圍繞腦機接口這一前沿新技術,上海將成立腦機接口與神經調控專業分會,匯聚基礎、臨牀、產業等“產學研醫”創新鏈多重力量,實現原創技術進一步突圍。2025年是中國腦機接口技術正式步入臨牀的關鍵一年。此前,北京、上海等地都已出臺腦機接口相關產業規劃,2030年前計劃完成5款以上侵入式產品臨牀試驗。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.